Assembly Biosciences Long Term Debt 2010-2025 | ASMB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Assembly Biosciences long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Assembly Biosciences long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19B
Dr Reddy's Laboratories (RDY)	$12.2B
BridgeBio Pharma (BBIO)	$8.8B
Bausch Health Cos (BHC)	$2.5B
Supernus Pharmaceuticals (SUPN)	$1.9B
Amphastar Pharmaceuticals (AMPH)	$1.1B
Personalis (PSNL)	$573M
Taysha Gene Therapies (TSHA)	$569M
Sol-Gel Technologies (SLGL)	$31M
Evoke Pharma (EVOK)	$7M
Teligent (TLGT)	$0M